It is a matter for NHS England and Monitor, the independent regulator, as to when and how a national tariff is created for stereotactic ablative radiotherapy. Relatively few changes are being made to the national tariff for 2014-15, in line with an approach of limiting uncertainty in the system and providing space for local experimentation in payment design, for example to support integrated care. Before expanding the scope of the mandatory national tariff, NHS England and Monitor will want to take advice to establish clinical priorities and the strength of the clinical evidence base. They will also want to be assured that any national prices they set are underpinned by robust cost data. This in no way prevents commissioners purchasing stereotactic ablative radiotherapy services at locally-agreed prices.